CY1117697T1 - Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii - Google Patents

Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii

Info

Publication number
CY1117697T1
CY1117697T1 CY20161100397T CY161100397T CY1117697T1 CY 1117697 T1 CY1117697 T1 CY 1117697T1 CY 20161100397 T CY20161100397 T CY 20161100397T CY 161100397 T CY161100397 T CY 161100397T CY 1117697 T1 CY1117697 T1 CY 1117697T1
Authority
CY
Cyprus
Prior art keywords
mhc class
chain
stables
bunch
toy
Prior art date
Application number
CY20161100397T
Other languages
English (en)
Inventor
Geir Åge Løset
Terje Frigstad
Inger Sandlie
Bjarne Bogen
Original Assignee
Universitetet I Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet I Oslo filed Critical Universitetet I Oslo
Publication of CY1117697T1 publication Critical patent/CY1117697T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με σταθεροποιημένα από δεσμούς δισουλφιδίων ανασυνδυασμένα μόρια του MHC τάξης II. Ειδικότερα, η παρούσα εφεύρεση παρέχει ένα ανασυνδυασμένο μόριο του MHC τάξης II, το οποίο περιλαμβάνει: (i) όλο ή μέρος του εξωκυτταρικού τμήματος μιας αλύσου α του MHC τάξης II • (ii) όλο ή μέρος του εξωκυτταρικού τμήματος μιας αλύσου β του MHC τάξης II • όπου τα (i) και (ii) παρέχουν μία επικράτεια δέσμευσης λειτουργικού πεπτιδίου και όπου τα (i) και (ii) συνδέονται μέσω ενός δεσμού δισουλφιδίων μεταξύ καταλοίπων κυστεΐνης που εντοπίζονται στην επικράτεια α2 της εν λόγω αλύσου α και στην επικράτεια β2 της εν λόγω αλύσου β, όπου τα εν λόγω κατάλοιπα κυστεΐνης δεν είναι παρόντα στις επικράτειας α2 και β2 του φυσικού MHC τάξης II. Μέθοδοι παραγωγής αυτών των μορίων σε προκαρυωτικά συστήματα και διάφορες χρήσεις αυτών των μορίων σχηματίζουν περαιτέρω απόψεις του θέματος.
CY20161100397T 2010-02-18 2016-05-11 Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii CY1117697T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30572810P 2010-02-18 2010-02-18
GBGB1002730.8A GB201002730D0 (en) 2010-02-18 2010-02-18 Product
US31657610P 2010-03-23 2010-03-23
PCT/GB2011/050325 WO2011101681A2 (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers

Publications (1)

Publication Number Publication Date
CY1117697T1 true CY1117697T1 (el) 2017-05-17

Family

ID=42113985

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100397T CY1117697T1 (el) 2010-02-18 2016-05-11 Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii

Country Status (18)

Country Link
US (2) US8828379B2 (el)
EP (1) EP2536746B1 (el)
JP (1) JP5537675B2 (el)
KR (1) KR101647176B1 (el)
CN (1) CN102947330B (el)
AU (1) AU2011217027B2 (el)
CA (1) CA2789492C (el)
CY (1) CY1117697T1 (el)
DK (1) DK2536746T3 (el)
ES (1) ES2572388T3 (el)
GB (1) GB201002730D0 (el)
HR (1) HRP20160475T1 (el)
HU (1) HUE027952T2 (el)
PL (1) PL2536746T3 (el)
RS (1) RS54744B1 (el)
RU (1) RU2604813C2 (el)
SI (1) SI2536746T1 (el)
WO (1) WO2011101681A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
RU2732148C2 (ru) * 2014-07-09 2020-09-11 Люпин Лимитед Двухцистронная бактериальная система экспрессии
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3538559A4 (en) * 2016-11-09 2020-06-24 UTI Limited Partnership RECOMBINANT PMHC CLASS II MOLECULES
AR111625A1 (es) 2017-04-27 2019-07-31 Juno Therapeutics Gmbh Reactivos de partículas oligoméricas y métodos de uso de los mismos
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
CN113366311A (zh) * 2018-09-28 2021-09-07 丹麦技术大学 使用可加载的检测分子的高通量表位鉴定和t细胞受体特异性测定
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP3719033A1 (en) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
EP4028412A2 (en) * 2019-09-13 2022-07-20 The Regents of The University of California Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
WO2021113297A1 (en) * 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
DE102020109447A1 (de) 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
EP0935607B1 (en) 1996-08-16 2004-07-28 The President And Fellows Of Harvard College Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
US6270772B1 (en) * 1997-09-16 2001-08-07 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
ID28040A (id) * 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
EP3144011A1 (en) * 2003-09-05 2017-03-22 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
CA2638892A1 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
ES2657480T3 (es) * 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
JP5154564B2 (ja) * 2006-12-01 2013-02-27 カール・ツァイス・エスエムティー・ゲーエムベーハー 像収差を低減するための交換可能で操作可能な補正構成を有する光学システム
EP2193199B1 (en) 2007-08-20 2013-11-06 Nextera AS Pvii phage display

Also Published As

Publication number Publication date
CA2789492A1 (en) 2011-08-25
US8828379B2 (en) 2014-09-09
CN102947330A (zh) 2013-02-27
DK2536746T3 (en) 2016-05-30
CN102947330B (zh) 2015-09-16
HUE027952T2 (en) 2016-11-28
PL2536746T3 (pl) 2016-08-31
RU2604813C2 (ru) 2016-12-10
JP2013519721A (ja) 2013-05-30
KR101647176B1 (ko) 2016-08-09
US9056920B2 (en) 2015-06-16
CA2789492C (en) 2017-04-18
GB201002730D0 (en) 2010-04-07
AU2011217027B2 (en) 2015-02-05
SI2536746T1 (sl) 2016-09-30
ES2572388T3 (es) 2016-05-31
US20130171668A1 (en) 2013-07-04
RU2012138302A (ru) 2014-03-27
EP2536746A2 (en) 2012-12-26
RS54744B1 (sr) 2016-10-31
KR20130009782A (ko) 2013-01-23
EP2536746B1 (en) 2016-04-20
US20140349315A1 (en) 2014-11-27
AU2011217027A1 (en) 2012-09-06
WO2011101681A2 (en) 2011-08-25
HRP20160475T1 (hr) 2016-06-03
WO2011101681A3 (en) 2011-12-08
JP5537675B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
CY1117697T1 (el) Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1121455T1 (el) Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
CY1121509T1 (el) Προ-πηκτικες ενωσεις και μεθοδοι χρησης αυτων
CY1121023T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
CY1122107T1 (el) Τροποποιημενες πρωτεϊνες δεσμευσης οι οποιες αναστελλουν την αλληλεπιδραση υποδοχεα vegf-a
CR20120366A (es) Proteínas de enlace a antigenos humanas que enlazan beta-klotho, receptores fgf y complejos de los mismos
CY1115801T1 (el) Συζευγματα παραγοντα viii πολυμερους
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1121962T1 (el) Υποδοχεις τ κυτταρου
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1119567T1 (el) Θεραπευτικα πεπτιδια
MD3365373T2 (ro) Molecule de legare care inhibă dezvoltarea cancerului
PE20170896A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
PE20081392A1 (es) Moleculas de enlace de lingo
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
NZ626945A (en) Chimeric factor viii polypeptides and uses thereof
CY1116011T1 (el) Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει
CY1115140T1 (el) Πεπτιδια και η χρηση τους